Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 35, Issue 2, 1996, Pages 273-279

  D'Amico, Anthony V ^a,c   Propert, Kathleen J ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

Prognostic factors; Prostate cancer; Prostate cancer volume; Prostate specific antigen; Radiation therapy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TUMOR VOLUME; ULTRASOUND;

EID: 0029971155     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(95)02389-5     Document Type: Article

References (22)

1. Aihara, M.; Lebovitz, R. M.; Wheeler, T. M.; Kinner, B. M.; Ohori, M.; Scardino, P. T. Prostate specific antigen and Gleason grade: An immunohistochemical study of prostate cancer. J. Urol. 151:1558-1564; 1994.
2. th ed. Philadelphia: J. P. Lippincott; 1992.
3. Benson, M. C.; Whang, I. S.; Olsson, C. A.; McMahon, D. J.; Cooner, W. H. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol. 147:817-821; 1992.
4. Blackwell, K. I.; Bostwick, D. G.; Myers, R. P.; Zincke, H.; Oesterling, J. E. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: The influence of prostate specific antigen cancer density. J. Urol. 151:1565-1570; 1994.
5. Carter, H. B.; Pearson, J. D.; Metter, J.; Brant, L. J.; Chan, D. W.; Andres, R.; Fozard, J. L.; Walsh, P. C. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220; 1992.
6. Catalona, W. J.; Richie, J. P.; DeKernion, J. B.; Ahmann, F. R.; Ratliff, T. L.; Dalkin, B. L.; Kavoussi, L. R.; MacFarlane, M. T.; Southwick, P. C. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves. J. Urol. 152:2037-2042; 1994.
7. Cox, D. R. Regression models and life tables. J. R. Stat. Soc. B34:1; 1972.
8. D'Amico, A. V.; Hanks, G. E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72:2638-2643; 1993.
9. Kaplan, E.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481; 1958.
10. Lepor, H.; Wang, B.; Shapiro, E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology 44:199-205; 1994.
11. Marks, L. S.; Treiger, B.; Dorey, F. J.; Fu, Y. S.; DeKernion, J. B. Morphometry of the prostate: I. Distribution of tissue components in hyperplastic glands. Urology 44:486-492, 1994.
12. McNeal, J. E. Cancer volume and site of origin of adenocarcinoma of the prostate: Relationship to local and distant spread. Hum. Pathol. 23:258-263; 1992.
13. McNeal, J. E.; Kindrachuk, R. A.; Freiha, F. S.; Bostwick, D. G.; Redwine, E. A.; Stamey, T. A. Patterns of progression in prostatic carcinoma. Lancet 1:60-63; 1986.
14. McNeal, J. E.; Villers, A. A.; Redwine, E. A.; Freiha, F. S.; Stamey, T. A. Capsular penetration in prostate cancer: Significance for natural history and treatment. Am. J. Surg. Pathol. 14:240-247; 1990.
15. McNeal, J. E.; Villers, A. A.; Redwine, E. A.; Freiha, F. S.; Stamey, T. A. Histologic differentiation, cancer volume in pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 66:1225-1233; 1990.
16. Myrtle, J. F.; Klimley, P. G.; Ivor, L. P.; Brun, J. F. Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer. Adv. Cancer Diag. Hybritech, Inc.; 1986.
17. Pilepich, M. V.; Krall, J. M.; Al-Sarraf, M.; John, M. J.; Scotte Doggett, R. L.; Sause, W. T.; Lawton, C. A.; Abrams, R. A.; Rotman, M.; Rubin, P.; Shipley, W. U.; Grignon, D.; Caplan, R.; Cox, J. D. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:623-630; 1995.
18. Stamey, T. A.; Freiha, F. S.; McNeal, J. E.; Redwine, E. A.; Whittemore, A. S.; Schmid, H. P. Localized prostate cancer: Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71:933-938; 1993.
19. Stamey, T. A.; Kabalin, J. N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J. Urol. 141:1070-1074; 1989.
20. Stamey, T. A.; McNeal, J. E.; Freiha, F. S.; Redwine, E. A. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol. 139:1235-1241; 1988.
21. Stamey, T. A.; Yang, N.; Hay, A. R.; McNeal, J.; Freiha, F. S.; Redwine, E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317:909-916; 1987.
22. Villers, A. A.; McNeal, J. E.; Redwine, E. A.; Freiha, F. S.; Stamey, T. A. Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J. Urol. 143:1183-1187; 1990.